Author | Dieter Zopf | OncLive

Author | Dieter Zopf

Articles

Clinical Development of Regorafenib Combinations in Pediatric Rhabdomyosarcoma

November 27, 2018

Video

Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses the clinical development of regorafenib (Stivarga) combinations in pediatric rhabdomyosarcoma.

Rationale for Regorafenib Combination Study in Pediatric Rhabdomyosarcoma

November 09, 2018

Video

Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses the rationale for a study of regorafenib (Stivarga) combinations in pediatric patients with rhabdomyosarcomas (RMS).

Optimal Regorafenib Combinations in Pediatric Rhabdomyosarcomas

November 02, 2018

Video

Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses the optimal partner for regorafenib (Stivarga) in pediatric rhabdomyosarcomas.

Identification of Combinations For Pediatric Rhabdomyosarcomas

October 22, 2018

Video

Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses a study analyzing effective combinations with regorafenib for the treatment of pediatric rhabdomyosarcomas.

x